Showing results (31-40 of 63) with videos related to

Sort By:
Pageof 7
Antimicrobial Agents and Chemotherapy|May 23, 2012
HIV gp120 H375 is unique to HIV-1 subtype CRF01_AE and confers strong resistance to the entry inhibitor BMS-599793, a candidate microbicide drugSusan M Schader, Susan P Colby-Germinario, Peter K Quashie, et al.
AIDS (London, England)|December 13, 2002
A V106M mutation in HIV-1 clade C viruses exposed to efavirenz confers cross-resistance to non-nucleoside reverse transcriptase inhibitorsBluma Brenner, Dan Turner, Maureen Oliveira, et al.
The Journal of Infectious Diseases|September 2, 2011
Transmission clustering drives the onward spread of the HIV epidemic among men who have sex with men in QuebecBluma G Brenner, Michel Roger, David Stephens, et al.
The Journal of Antimicrobial Chemotherapy|June 11, 2013
The preferential selection of K65R in HIV-1 subtype C is attenuated by nucleotide polymorphisms at thymidine analogue mutation sitesCédric F Invernizzi, Dimitrios Coutsinos, Maureen Oliveira, et al.
Antiviral Therapy|September 6, 2002
Co-receptor usage and HIV-1 intra-clade C polymorphisms in the protease and reverse transcriptase genes of HIV-1 isolates from Ethiopia and BotswanaHugues Loemba, Bluma Brenner, Michael A Parniak, et al.
The Journal of Antimicrobial Chemotherapy|September 5, 2012
In vitro and structural evaluation of PL-100 as a potential second-generation HIV-1 protease inhibitorEugene L Asahchop, Maureen Oliveira, Peter K Quashie, et al.
Journal of Virology|September 18, 2015
Characterization of the Drug Resistance Profiles of Integrase Strand Transfer Inhibitors in Simian Immunodeficiency Virus SIVmac239Said A Hassounah, Yannan Liu, Peter K Quashie, et al.
Antimicrobial Agents and Chemotherapy|September 17, 2014
HIV-1 group O integrase displays lower enzymatic efficiency and higher susceptibility to raltegravir than HIV-1 group M subtype B integraseAgnès Depatureaux, Peter K Quashie, Thibault Mesplède, et al.
The Journal of Antimicrobial Chemotherapy|February 9, 2012
The role of polymorphisms at position 89 in the HIV-1 protease gene in the development of drug resistance to HIV-1 protease inhibitorsJorge L Martinez-Cajas, Mark A Wainberg, Maureen Oliveira, et al.
Antimicrobial Agents and Chemotherapy|July 17, 2013
Basis for early and preferential selection of the E138K mutation in HIV-1 reverse transcriptaseMatthew McCallum, Maureen Oliveira, Ruxandra-Ilinca Ibanescu, et al.
Pageof 7